A Linear Discriminant Analysis Model Based on the Changes of 7 Proteins in Plasma Predicts Response to Anlotinib Therapy in Advanced Non-Small Cell Lung Cancer Patients

A Linear Discriminant Analysis Model Based on the Changes of 7 Proteins in Plasma Predicts Response to Anlotinib Therapy in Advanced Non-Small Cell Lung Cancer Patients

BackgroundAnlotinib is a multi-targeted tyrosine kinase inhibitor mainly targeting angiogenesis signaling. The predictive marker of anlotinib’s efficacy remains elusive. This study was designed to explore the predictive marker of anlotinib in non-small cell lung cancer (NSCLC).MethodsWe prospectivel...

Full description

Bibliographic Details
Main Authors: Fei Xu, Haiyan Xu, Zhiyi Wan, Guangjian Yang, Lu Yang, Xueying Wu, Jin Song, Yan Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-01-01
Series:Frontiers in Oncology
Subjects:
anlotinib
non-small cell lung cancer
linear discriminant analysis
predict
progression-free survival
protein
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.756902/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.756902/full

Similar Items